Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Jul;37(7):1543–1546. doi: 10.1128/aac.37.7.1543

Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model.

J A Fishman 1, S F Queener 1, R S Roth 1, M S Bartlett 1
PMCID: PMC188010  PMID: 8395791

Abstract

Five topoisomerase II inhibitors (amsacrine [m-AMSA], two epipodophyllotoxins, and two quinolones) and the alkaloid camptothecin (a topoisomerase I inhibitor) were evaluated to assess their activities against Pneumocystis carinii. In vitro, both etoposide (VP-16) and teniposide (VM-26) at 1 microgram/ml suppressed P. carinii growth. Amsacrine was toxic to P. carinii and to the feeder cells in vitro. Camptothecin suppressed the growth of P. carinii in vitro only at 100 micrograms/ml. Studies in immunosuppressed mice demonstrated the efficacy of teniposide against P. carinii pneumonia, but successful administration of teniposide was schedule dependent with significant toxicity at therapeutic dosages.

Full text

PDF
1546

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barre J., Houin G., Tillement J. P. Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans. J Pharm Sci. 1984 Oct;73(10):1379–1382. doi: 10.1002/jps.2600731014. [DOI] [PubMed] [Google Scholar]
  2. Bartlett M. S., Edlind T. D., Durkin M. M., Shaw M. M., Queener S. F., Smith J. W. Antimicrotubule benzimidazoles inhibit in vitro growth of Pneumocystis carinii. Antimicrob Agents Chemother. 1992 Apr;36(4):779–782. doi: 10.1128/aac.36.4.779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bartlett M. S., Eichholtz R., Smith J. W. Antimicrobial susceptibility of Pneumocystis carinii in culture. Diagn Microbiol Infect Dis. 1985 Sep;3(5):381–387. doi: 10.1016/0732-8893(85)90076-8. [DOI] [PubMed] [Google Scholar]
  4. Bartlett M. S., Fishman J. A., Durkin M. M., Queener S. F., Smith J. W. Pneumocystis carinii: improved models to study efficacy of drugs for treatment or prophylaxis of Pneumocystis pneumonia in the rat (Rattus spp.). Exp Parasitol. 1990 Jan;70(1):100–106. doi: 10.1016/0014-4894(90)90089-u. [DOI] [PubMed] [Google Scholar]
  5. Bartlett M. S., Fishman J. A., Queener S. F., Durkin M. M., Jay M. A., Smith J. W. New rat model of Pneumocystis carinii infection. J Clin Microbiol. 1988 Jun;26(6):1100–1102. doi: 10.1128/jcm.26.6.1100-1102.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bartlett M. S., Queener S. F., Durkin M. M., Shaw M. A., Smith J. W. Inoculated mouse model of Pneumocystis carinii infection. Diagn Microbiol Infect Dis. 1992 Feb;15(2):129–134. doi: 10.1016/0732-8893(92)90036-s. [DOI] [PubMed] [Google Scholar]
  7. Bartlett M. S., Queener S. F., Tidwell R. R., Milhous W. K., Berman J. D., Ellis W. Y., Smith J. W. 8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models. Antimicrob Agents Chemother. 1991 Feb;35(2):277–282. doi: 10.1128/aac.35.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bouchard P., Sai P., Reach G., Caubarrère I., Ganeval D., Assan R. Diabetes mellitus following pentamidine-induced hypoglycemia in humans. Diabetes. 1982 Jan;31(1):40–45. [PubMed] [Google Scholar]
  9. Drlica K., Franco R. J. Inhibitors of DNA topoisomerases. Biochemistry. 1988 Apr 5;27(7):2253–2259. doi: 10.1021/bi00407a001. [DOI] [PubMed] [Google Scholar]
  10. Dykstra C. C., Tidwell R. R. Inhibition of topoisomerases from Pneumocystis carinii by aromatic dicationic molecules. J Protozool. 1991 Nov-Dec;38(6):78S–81S. [PubMed] [Google Scholar]
  11. Gellert M. DNA topoisomerases. Annu Rev Biochem. 1981;50:879–910. doi: 10.1146/annurev.bi.50.070181.004311. [DOI] [PubMed] [Google Scholar]
  12. Jaffe H. W., Bregman D. J., Selik R. M. Acquired immune deficiency syndrome in the United States: the first 1,000 cases. J Infect Dis. 1983 Aug;148(2):339–345. doi: 10.1093/infdis/148.2.339. [DOI] [PubMed] [Google Scholar]
  13. Jensen P. B., Roed H., Skovsgaard T., Friche E., Vindeløv L., Hansen H. H., Spang-Thomsen M. Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation. Cancer Chemother Pharmacol. 1990;27(3):194–198. doi: 10.1007/BF00685712. [DOI] [PubMed] [Google Scholar]
  14. Johnson D. H., Hainsworth J. D., Hande K. R., Greco F. A. Current status of etoposide in the management of small cell lung cancer. Cancer. 1991 Jan 1;67(1 Suppl):231–244. doi: 10.1002/1097-0142(19910101)67:1+<231::aid-cncr2820671305>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  15. Koga H. High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1987 Dec;31(12):1904–1908. doi: 10.1128/aac.31.12.1904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kovacs J. A., Masur H. Pneumocystis carinii pneumonia: therapy and prophylaxis. J Infect Dis. 1988 Jul;158(1):254–259. doi: 10.1093/infdis/158.1.254. [DOI] [PubMed] [Google Scholar]
  17. Lachaal M., Venuto R. C. Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine. Am J Med. 1989 Sep;87(3):260–263. doi: 10.1016/s0002-9343(89)80147-0. [DOI] [PubMed] [Google Scholar]
  18. Montay G., Goueffon Y., Roquet F. Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. Antimicrob Agents Chemother. 1984 Apr;25(4):463–472. doi: 10.1128/aac.25.4.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Queener S. F., Bartlett M. S., Jay M. A., Durkin M. M., Smith J. W. Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection. Antimicrob Agents Chemother. 1987 Sep;31(9):1323–1327. doi: 10.1128/aac.31.9.1323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sands M., Kron M. A., Brown R. B. Pentamidine: a review. Rev Infect Dis. 1985 Sep-Oct;7(5):625–634. doi: 10.1093/clinids/7.5.625. [DOI] [PubMed] [Google Scholar]
  21. Wharton J. M., Coleman D. L., Wofsy C. B., Luce J. M., Blumenfeld W., Hadley W. K., Ingram-Drake L., Volberding P. A., Hopewell P. C. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med. 1986 Jul;105(1):37–44. doi: 10.7326/0003-4819-105-1-37. [DOI] [PubMed] [Google Scholar]
  22. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES